Effects of CPT‐11 in combination with other anti‐cancer agents in culture

Kano, Yasuhiko; Suzuki, Kenichi; Akutsu, Miyuki; Suda, Kazuto; Inoue, Yoshiharu; Yoshida, Minoru; Sakamoto, Shinobu; Miura, Yasusada

doi:10.1002/ijc.2910500420

Cited by 197 publications

(114 citation statements)

References 18 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…Figure 1 shows a schematic isobologram. The theoretical basis of the isobologram has been described previously (Steel and Peckham, 1979;Kano et al, 1988Kano et al, , 1992. Three isoeffect curves were constructed based upon the dose -response curves of paclitaxel and 5-fluorouracil.…”

mentioning

confidence: 99%

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

Kano

Akutsu²,

Tsunoda³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PAI and WiDr. The cells were exposed simultaneously to paclitaxel and to 5-fluorouracil for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days respectively. In another experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was determined by MTT reduction assay. The effects of drug combinations at IC80 were analysed by the isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent. Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549, MCF7 and WiDr cell lines, whereas it showed additive effects in PAI cells. Sequential exposure to paclitaxel followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PAl cells. Whereas it showed additive effects in WiDr cells. These findings suggest that maximum cytotoxic effects can be obtained when paclitaxel precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PAl and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration. These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.

show abstract

mentioning

confidence: 99%

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

Kano

Akutsu²,

Tsunoda³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[15][16][17] Briefly, three isoeffect curves were drawn (mode 1, mode 2a, and mode 2b) based on the dose-response curves of the recombinant adenovirus and the combined drug (Fig 1). Mode 1 indicates that when the dose of AdCAp53 was chosen, an increased effect was produced by the combined drug.…”

Section: Isobologram Analysismentioning

confidence: 99%

“…AdCAp53 inhibited the cell growth of NCI-H157 cells and NCI-H1299 cells in a dose-dependent manner. At a concentration of 0.5 multiplicities of infection (MOI) and 0.03 (MOI) for NCI-H157 and NCI-H1299, respectively, cell growth was inhibited by 15% of the control cell growth (ID 15 ). In our preliminary experiments, the cell growth was not influenced by AdLacZ when using higher concentrations of the virus (Յ10 MOI) (data not shown).…”

Section: Dose-response Curves Of Recombinant Adenovirusmentioning

confidence: 99%

Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells

Osaki¹,

Nakanishi²,

Takayama³

et al. 2000

Cancer Gene Ther

View full text Add to dashboard Cite

The aim of the present study is to identify the optimal anticancer agents for use in combination with gene therapy using wild-type (wt) p53 gene transfer. We used adenoviral vectors expressing human wt p53 (AdCAp53) and investigated the effects of wt p53 gene transfer in combination with 12 anticancer agents on a human pulmonary squamous cell carcinoma cell line, NCI-H157, and a human pulmonary large cell carcinoma cell line, NCI-H1299. Solutions containing anticancer agents at various concentrations were added followed by the addition of recombinant adenovirus solutions; after a 5-day incubation period, the anticancer activity was then evaluated by a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay. Each 50% inhibitory concentration was calculated based on the dose-response curves. The agents showing a high degree of effectiveness on NCI-H157 cells were cisplatin (CDDP), 5-fluorouracil (5-FU), bleomycin, and 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of irinotecan (CPT-11); conversely, cyclophosphamide and paclitaxel showed a low degree of effectiveness. Based on these data, an isobologram was performed to investigate the interaction between AdCAp53 and some anticancer agents. A supra-additive effect was thus observed for 5-FU and SN-38 on NCI-H157 cells. An additive effect was also observed for CDDP, paclitaxel, bleomycin, and cyclophosphamide on NCI-H157 cells. CDDP, paclitaxel, 5-FU, and SN-38 had an additive effect on NCI-H1299 cells. No drug showed any subadditive or protective effects. These findings suggest that CPT-11 and 5-FU may thus be useful as possible anticancer agents for use in a combination therapy regimen using wt p53 gene transfer. CDDP and CPT-11 had a significant antitumoral effect on H157 cell xenografts of nude mice in vivo. These results indicate that CPT-11 as well as CDDP would be a candidate for the combination of chemotherapy and gene therapy for non-small cell lung cancer. Cancer Gene Therapy (2000) 7, 300 -307

show abstract

“…The theoretical basis of this method has been described previously (Steel et al, 1979;Kano et al, 1988;Kano et al, 1992). Based upon the dose-response curves of ICRF-154 other drug combinations, three isoeffect lines, mode I and mode II, were drawn ( Figure 2).…”

Section: Isobologram Analysismentioning

confidence: 99%

The effects of ICRF-154 in combination with other anticancer agents in vitro

Kano

Narita²,

Suzuki³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

Summary We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-I1, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for

show abstract

Effects of CPT‐11 in combination with other anti‐cancer agents in culture

Cited by 197 publications

References 18 publications

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells

The effects of ICRF-154 in combination with other anticancer agents in vitro

Contact Info

Product

Resources

About